All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Ongoing | 2004-001563-21 | A Phase II, Single-Arm Trial of Naked Epratuzumab, an Anti-CD22 Humanized Antibody, in Patients with Waldenström's Macroglobulinemia | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2005-000705-59 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzumab in Patients with Acute Severe SLE Flares Excluding the Renal or Neurologic Systems | 2007-03-08 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2005-000706-31 | A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi- Center Study of Epratuzumab in Patients with Active Systemic Lupus Erythematosus | 2007-02-16 | bad-data |
| Exempt | 2008-000434-47 | A Phase I/II Study of Immunotherapy with Subcutaneous Administered Veltuzumab (hA20) in Patients with CD20+ Non-Hodgkin's Lymphoma or Chronic Lyphocytic Leukemia | not-yet-due | |
| Exempt | 2008-003993-16 | A Phase Ib/II Study of Fractionated 90-Y-hPAM4 Plus Gemcitabine in Patients with Previously Untreated Advanced Pancreatic Cancer | not-yet-due | |
| Reported results | 2013-004516-21 | An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan plus Low-Dose Gemcitabine Versus Placebo plus Low-Dose Gemcitabine in Patients with Metastatic ... | 2016-03-14 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-003019-21 | An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Rece... | 2020-12-03 | bad-data |
| Other | 2018-001167-23 | A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy Étude de phase II en ouvert de l’IMMU 132 da... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2018-004201-33 | Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negativ... | 2023-10-20 | bad-data |
| Other | 2019-004868-22 | Open-label Rollover Study to Evaluate Long-Term Safety in Subjects with Metastatic Solid Tumors that are Benefiting from Continuation of Therapy with Sacituzumab Govitecan. | not-yet-due | |
| Ongoing | 2020-002964-29 | A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer Studio randomi... | not-yet-due |